Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience

BACKGROUND: Based on recent data from clinical trials, the immune checkpoint inhibitor pembrolizumab prolongs survival and has a good toxicity profile in patients with advanced or metastatic melanoma. However, the question remains whether these results are transmitted into daily clinical practice. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Hribernik, Nezka, Boc, Marko, Ocvirk, Janja, Knez-Arbeiter, Jasna, Mesti, Tanja, Ignjatovic, Marija, Rebersek, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087416/
https://www.ncbi.nlm.nih.gov/pubmed/31955148
http://dx.doi.org/10.2478/raon-2020-0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087416/
https://www.ncbi.nlm.nih.gov/pubmed/31955148
http://dx.doi.org/10.2478/raon-2020-0003

Ejemplares similares